Get the Stockscreener App
1.40
1.45%
0.02
Medicinova Inc stock is traded at $1.40, with a volume of 15,881.
It is up +1.45% in the last 24 hours and down -10.26% over the past month.
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
See More
Previous Close:
$1.38
Open:
$1.41
24h Volume:
15,881
Relative Volume:
0.02
Market Cap:
$68.80M
Revenue:
$134.60K
Net Income/Loss:
$-11.81M
P/E Ratio:
-5.8115
EPS:
-0.2409
Net Cash Flow:
$-10.05M
1W Performance:
+8.53%
1M Performance:
-10.26%
6M Performance:
+12.00%
1Y Performance:
-35.19%
1-Day Range:
$1.38
$1.41
1-Week Range:
$1.28
$1.41
52-Week Range:
$1.13
$2.15
Medicinova Inc Stock (MNOV) Company Profile
Name
Medicinova Inc
Sector
Industry
Phone
858-373-1500
Address
4275 EXECUTIVE SQUARE, LA JOLLA, CA
Compare MNOV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.40 | 67.82M | 134.60K | -11.81M | -10.05M | -0.2409 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.92 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.55 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.75 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
801.69 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.75 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-21 | Initiated | Maxim Group | Buy |
| Mar-25-19 | Resumed | B. Riley FBR | Buy |
| Mar-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-18-17 | Initiated | Credit Suisse | Outperform |
| Jan-04-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-24-12 | Downgrade | MLV & Co | Buy → Hold |
| Oct-18-11 | Reiterated | MLV Capital | Buy |
| Jun-22-11 | Initiated | Global Hunter Securities | Buy |
| May-12-10 | Initiated | Wedbush | Outperform |
| Nov-12-08 | Reiterated | Ladenburg Thalmann | Buy |
| May-15-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jul-09-07 | Initiated | Punk, Ziegel & Co | Buy |
View All
Medicinova Inc Stock (MNOV) Latest News
MediciNova, Inc. Provides Shareholder Update on Clinical Trials and Strategic Developments for 2026 - Quiver Quantitative
2026 New Year’s Greetings from the CEO - Bluefield Daily Telegraph
MediciNova (NASDAQ:MNOV) Shares Cross Above Two Hundred Day Moving Average – What’s Next? - Defense World
MNOVProspectus Filed Pursuant to Rule 424(b)(5) (424b5) - ADVFN
Retail Trends: Is MediciNova Inc stock a top pick in earnings seasonWeekly Profit Recap & High Conviction Buy Zone Picks - moha.gov.vn
4875.T Jumps 8.7% Today: Positive Momentum in Biotech - Meyka
MediciNova enters $50 million equity distribution agreement with Lucid Capital - Investing.com Nigeria
MediciNova Inc enters $50 million equity distribution agreement with Lucid Capital Markets - marketscreener.com
Medicinova IncOn Dec 29, Entered $50 Million Equity Distribution Agreement With Lucid Capital Markets- SEC Filing - TradingView — Track All Markets
MediciNova Establishes Flexible At-The-Market Equity Program - TipRanks
MediciNova enters $50 million equity distribution agreement with Lucid Capital By Investing.com - Investing.com South Africa
MediciNova Signs Equity Distribution Agreement With Lucid Capital Markets - TradingView — Track All Markets
Form 424B5 MEDICINOVA INC - StreetInsider
MediciNova, Inc. (NASDAQ:MNOV) Sees Large Decline in Short Interest - MarketBeat
Bank Watch: Why MediciNova Inc. stock could benefit from AI revolutionTrade Analysis Report & AI Driven Stock Price Forecasts - moha.gov.vn
Is MediciNova Inc. stock a top pick in earnings seasonWeekly Investment Summary & Growth Focused Entry Point Reports - Bölüm Sonu Canavarı
Why MediciNova Inc. stock could benefit from AI revolutionQuarterly Portfolio Summary & Verified Technical Trade Signals - Улправда
Will MediciNova Inc. stock outperform value stocksDollar Strength & Real-Time Stock Movement Alerts - DonanımHaber
MediciNova (NASDAQ:MNOV) Receives Buy Rating from D. Boral Capital - Defense World
After-Hours Biotech Rally: Inspira, MediciNova, DiaMedica Therapeutics Among Gainers - Nasdaq
Aug Swings: Why MediciNova Inc. stock could benefit from AI revolution2025 Technical Overview & Verified Short-Term Plans - Улправда
D. Boral Capital Maintains MediciNova (MNOV) Buy Recommendation - Nasdaq
How MediciNova Inc. stock performs in rising dollar environmentEarnings Performance Report & Community Shared Stock Ideas - Улправда
MediciNova completes enrollment in chemotherapy neuropathy trial By Investing.com - Investing.com Nigeria
MNOV: Analyst Jason Kolbert Maintains 'Buy' Rating with $9 Price - GuruFocus
D. Boral Capital Reaffirms Buy Rating for MediciNova (NASDAQ:MNOV) - MarketBeat
MediciNova Completes Enrollment in a Phase 2 Study of Colorectal Cancer Drug - marketscreener.com
MediciNova completes enrollment in chemotherapy neuropathy trial - Investing.com India
MediciNova, Inc. Completes Patient Enrollment in Phase 2 OXTOX Study for MN-166 in Metastatic Colorectal Cancer Patients - Quiver Quantitative
MediciNova Announces Completion of Patient Enrollment - GlobeNewswire
Bank Watch: Will MediciNova Inc stock beat EPS estimatesJuly 2025 Breakouts & Community Driven Trade Alerts - moha.gov.vn
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving Average – Here’s What Happened - Defense World
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
Free cash flow per share of MediciNova, Inc. – TSE:4875 - TradingView — Track All Markets
MediciNova (NASDAQ:MNOV) Receives “Buy” Rating from D. Boral Capital - Defense World
MediciNova (MNOV) Analyst Rating Maintained at 'Buy' with $9.00 - GuruFocus
MediciNova completes enrollment in phase 2b/3 ALS clinical trial - Investing.com
MediciNova Provides Update on COMBAT-ALS Study of MN-166 for Amyotrophic Lateral Sclerosis - Quiver Quantitative
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND - The Manila Times
MediciNova completes enrollment in phase 2b/3 ALS clinical trial By Investing.com - Investing.com UK
MediciNova (NASDAQ: MNOV) fully enrolls 234-patient Phase 2b/3 ALS ALS trial, targets 2026 top-line data - Stock Titan
Is MediciNova Inc a good long term investmentTake Profit Strategies & Ride the Wave of Market-Beating Growth - earlytimes.in
Gainers Report: Can MediciNova Inc stock continue upward trendShare Buyback & Growth Focused Investment Plans - BỘ NỘI VỤ
Can MediciNova Inc. stock sustain free cash flow growthMarket Volume Report & Free Weekly Chart Analysis and Trade Guides - Newser
EBITDA per share of MediciNova, Inc. – TSE:4875 - TradingView
Can MediciNova Inc. stock continue upward trendJuly 2025 Price Swings & Verified Entry Point Signals - Newser
MediciNova (MNOV) Stock Analysis Report | Financials & Insights - Benzinga
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
MediciNova, Inc. (MNOV) 9.22% in After-hours: Amid Routine Trading - Stocks Telegraph
MediciNova Reports Significant Milestone in MN-001 Program Following Journal Publication on Cholesterol Efflux Mechanism - Quiver Quantitative
Message from the CEO to MediciNova Shareholders - GlobeNewswire
Medicinova Inc Stock (MNOV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):